<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>Bloodü©∏Doctor | Inherited Aplastic Anaemia & BMF Syndromes</title>
    <link rel="preconnect" href="https://fonts.googleapis.com" />
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
    <link
      href="https://fonts.googleapis.com/css2?family=Fraunces:opsz,wght@9..144,500;9..144,600;9..144,700&family=Sora:wght@300;400;500;600;700&display=swap"
      rel="stylesheet"
    />
    <style>
      :root {
        --ink: #11131a;
        --slate: #2b2f3a;
        --muted: #5c6170;
        --blood: #8b0e1c;
        --blood-soft: #b73345;
        --gold: #d7a35d;
        --teal: #0f766e;
        --teal-soft: #cde8e4;
        --rose: #f4d8dd;
        --ivory: #f7f2ed;
        --mist: #f3f6f8;
        --white: #ffffff;
        --shadow: 0 28px 60px rgba(17, 19, 26, 0.18);
        --radius: 22px;
      }

      * {
        box-sizing: border-box;
      }

      body {
        margin: 0;
        font-family: "Sora", system-ui, -apple-system, sans-serif;
        color: var(--ink);
        background: radial-gradient(circle at top, #ffffff 0%, #f6efe8 38%, #efe3d7 100%);
      }

      html {
        scroll-behavior: smooth;
      }

      a {
        color: inherit;
        text-decoration: none;
      }

      button,
      input {
        font-family: inherit;
      }

      .page {
        min-height: 100vh;
        display: flex;
        flex-direction: column;
      }

      .hero {
        position: relative;
        padding: 42px 6vw 64px;
        overflow: hidden;
      }

      .hero::before,
      .hero::after {
        content: "";
        position: absolute;
        border-radius: 999px;
        opacity: 0.85;
        z-index: 0;
      }

      .hero::before {
        width: 420px;
        height: 420px;
        background: radial-gradient(circle, rgba(183, 51, 69, 0.45) 0%, rgba(183, 51, 69, 0) 70%);
        right: -150px;
        top: -160px;
      }

      .hero::after {
        width: 360px;
        height: 360px;
        background: radial-gradient(circle, rgba(15, 118, 110, 0.35) 0%, rgba(15, 118, 110, 0) 70%);
        left: -140px;
        bottom: -160px;
      }

      .nav {
        display: flex;
        align-items: center;
        justify-content: space-between;
        position: relative;
        z-index: 1;
        gap: 20px;
      }

      .brand {
        font-size: 1.5rem;
        font-weight: 700;
      }

      .nav-meta {
        display: flex;
        gap: 16px;
        align-items: center;
        font-weight: 600;
        color: rgba(17, 19, 26, 0.7);
      }

      .pill {
        padding: 8px 14px;
        border-radius: 999px;
        background: var(--ivory);
        font-size: 0.85rem;
      }

      .hero-grid {
        margin-top: 50px;
        display: grid;
        grid-template-columns: repeat(2, minmax(0, 1fr));
        gap: 40px;
        align-items: center;
        position: relative;
        z-index: 1;
      }

      .hero-copy h1 {
        font-family: "Fraunces", serif;
        font-size: clamp(2.6rem, 4vw, 4.2rem);
        line-height: 1.05;
        margin: 0 0 16px;
      }

      .hero-copy p {
        font-size: 1.05rem;
        line-height: 1.7;
        color: rgba(17, 19, 26, 0.72);
        margin: 0 0 26px;
      }

      .cta-row {
        display: flex;
        align-items: center;
        gap: 14px;
        flex-wrap: wrap;
      }

      .cta-primary {
        background: var(--blood);
        color: #fff;
        border: none;
        padding: 16px 32px;
        border-radius: 999px;
        font-weight: 600;
        font-size: 1rem;
        cursor: pointer;
        box-shadow: 0 18px 40px rgba(139, 14, 28, 0.28);
        transition: transform 0.2s ease, box-shadow 0.2s ease;
      }

      .cta-primary:hover {
        transform: translateY(-2px);
        box-shadow: 0 24px 48px rgba(139, 14, 28, 0.35);
      }

      .cta-secondary {
        color: rgba(17, 19, 26, 0.65);
        font-weight: 600;
      }

      .hero-panel {
        background: #fff;
        border-radius: var(--radius);
        padding: 24px;
        box-shadow: var(--shadow);
        display: grid;
        gap: 18px;
      }

      .panel-title {
        font-weight: 700;
        font-size: 1.1rem;
      }

      .stat-grid {
        display: grid;
        gap: 14px;
      }

      .stat {
        display: flex;
        justify-content: space-between;
        padding: 12px 14px;
        border-radius: 14px;
        background: var(--mist);
        font-size: 0.95rem;
      }

      .stat strong {
        color: var(--blood);
      }

      .section {
        padding: 64px 6vw;
      }

      .section-title {
        font-size: 2rem;
        font-family: "Fraunces", serif;
        margin-bottom: 12px;
      }

      .section-sub {
        color: rgba(17, 19, 26, 0.68);
        max-width: 820px;
        line-height: 1.7;
        margin-bottom: 28px;
      }

      .control-bar {
        display: flex;
        gap: 18px;
        align-items: center;
        flex-wrap: wrap;
        background: var(--white);
        border-radius: 16px;
        padding: 16px 18px;
        box-shadow: var(--shadow);
      }

      .toggle {
        border: 1px solid rgba(17, 19, 26, 0.2);
        background: #fff;
        border-radius: 999px;
        padding: 10px 16px;
        font-weight: 600;
        cursor: pointer;
      }

      .search {
        flex: 1;
        min-width: 220px;
        border: 1px solid rgba(17, 19, 26, 0.2);
        border-radius: 999px;
        padding: 12px 16px;
        font-size: 0.95rem;
      }

      .map {
        display: grid;
        grid-template-columns: repeat(auto-fit, minmax(220px, 1fr));
        gap: 16px;
        margin-top: 28px;
      }

      .map-card {
        background: #fff;
        border-radius: 18px;
        padding: 18px;
        box-shadow: var(--shadow);
        display: grid;
        gap: 12px;
      }

      .map-card button {
        border: none;
        background: var(--teal);
        color: #fff;
        padding: 10px 14px;
        border-radius: 999px;
        font-weight: 600;
        cursor: pointer;
      }

      .module {
        margin-top: 42px;
        padding: 28px;
        border-radius: var(--radius);
        background: #fff;
        box-shadow: var(--shadow);
      }

      .module-head {
        display: flex;
        justify-content: space-between;
        align-items: center;
        gap: 16px;
        flex-wrap: wrap;
        margin-bottom: 18px;
      }

      .module-head h3 {
        margin: 0;
        font-family: "Fraunces", serif;
        font-size: 1.6rem;
      }

      .module-tag {
        background: var(--rose);
        color: var(--blood);
        padding: 6px 14px;
        border-radius: 999px;
        font-weight: 600;
        font-size: 0.85rem;
      }

      .module-grid {
        display: grid;
        grid-template-columns: repeat(2, minmax(0, 1fr));
        gap: 20px;
      }

      .card {
        border-radius: 18px;
        padding: 18px;
        background: var(--mist);
        display: grid;
        gap: 12px;
      }

      .card.deep {
        background: #fff7f2;
        border: 1px solid rgba(139, 14, 28, 0.12);
      }

      .card h4 {
        margin: 0;
        font-size: 1.1rem;
      }

      .card p {
        margin: 0;
        color: rgba(17, 19, 26, 0.7);
        line-height: 1.6;
      }

      .card ul {
        margin: 0;
        padding-left: 18px;
        color: rgba(17, 19, 26, 0.75);
        line-height: 1.6;
      }

      .callout {
        margin-top: 18px;
        border-radius: 16px;
        padding: 16px 18px;
        background: var(--teal-soft);
        display: grid;
        gap: 8px;
      }

      .callout.high-yield {
        background: #fff3e6;
        border: 1px solid rgba(215, 163, 93, 0.45);
      }

      .callout strong {
        text-transform: uppercase;
        font-size: 0.8rem;
        letter-spacing: 0.08em;
      }

      .table-wrap {
        overflow-x: auto;
      }

      table {
        width: 100%;
        border-collapse: collapse;
        font-size: 0.92rem;
      }

      th,
      td {
        text-align: left;
        padding: 10px 12px;
        border-bottom: 1px solid rgba(17, 19, 26, 0.1);
        vertical-align: top;
      }

      th {
        color: var(--slate);
        font-weight: 700;
        background: #f0e9e3;
      }

      .flow {
        display: grid;
        gap: 14px;
        margin-top: 12px;
      }

      .flow-step {
        background: #f3f5f7;
        border-radius: 14px;
        padding: 14px 16px;
        display: flex;
        align-items: center;
        gap: 12px;
      }

      .flow-step span {
        width: 28px;
        height: 28px;
        border-radius: 50%;
        background: var(--blood);
        color: #fff;
        display: inline-flex;
        align-items: center;
        justify-content: center;
        font-weight: 600;
        font-size: 0.9rem;
      }

      .diagram {
        width: 100%;
        border-radius: 18px;
        background: #fff;
        border: 1px solid rgba(17, 19, 26, 0.08);
        box-shadow: 0 16px 28px rgba(17, 19, 26, 0.08);
      }

      details {
        border-radius: 16px;
        border: 1px solid rgba(17, 19, 26, 0.1);
        padding: 12px 14px;
        background: #fff;
      }

      details summary {
        cursor: pointer;
        font-weight: 600;
      }

      .quiz {
        margin-top: 18px;
        background: #f8f0f1;
        border-radius: 16px;
        padding: 16px;
        display: grid;
        gap: 10px;
      }

      .quiz button {
        border: none;
        background: var(--blood-soft);
        color: #fff;
        padding: 8px 14px;
        border-radius: 999px;
        cursor: pointer;
        font-weight: 600;
        width: fit-content;
      }

      .answer {
        display: none;
        color: rgba(17, 19, 26, 0.7);
      }

      .answer.active {
        display: block;
      }

      .cta-band {
        margin-top: 48px;
        padding: 26px 28px;
        border-radius: var(--radius);
        background: linear-gradient(120deg, #8b0e1c, #5f0b14);
        color: #fff;
        display: flex;
        flex-wrap: wrap;
        justify-content: space-between;
        align-items: center;
        gap: 16px;
      }

      .cta-band p {
        margin: 6px 0 0;
        color: rgba(255, 255, 255, 0.85);
      }

      .cta-band button {
        background: #fff;
        color: var(--blood);
        border: none;
        padding: 12px 18px;
        border-radius: 999px;
        font-weight: 700;
        cursor: pointer;
      }

      .disclaimer {
        margin-top: 26px;
        color: rgba(17, 19, 26, 0.6);
        font-size: 0.9rem;
      }

      .footer {
        padding: 28px 6vw 42px;
        background: #13151d;
        color: rgba(255, 255, 255, 0.78);
        display: flex;
        justify-content: space-between;
        flex-wrap: wrap;
        gap: 12px;
      }

      .simplify .deep,
      .simplify details,
      .simplify .table-wrap {
        display: none;
      }

      @media (max-width: 980px) {
        .hero-grid {
          grid-template-columns: 1fr;
        }

        .module-grid {
          grid-template-columns: 1fr;
        }
      }

      @media (max-width: 720px) {
        .hero {
          padding: 34px 5vw 54px;
        }

        .section {
          padding: 52px 5vw;
        }

        .nav {
          flex-direction: column;
          align-items: flex-start;
        }

        .cta-band {
          flex-direction: column;
          align-items: flex-start;
        }
      }
    </style>
  </head>
  <body>
    <div class="page">
      <header class="hero" id="top">
        <nav class="nav">
          <div class="brand">Bloodü©∏Doctor</div>
          <div class="nav-meta">
            <div class="pill">Dr Abdul Mannan FRCPath FCPS</div>
            <div class="pill">blooddoctor.co@gmail.com</div>
          </div>
        </nav>

        <div class="hero-grid">
          <div class="hero-copy">
            <div class="pill">Chapter 30 ¬∑ Hoffbrand Postgraduate Haematology</div>
            <h1>Inherited Aplastic Anaemia & Bone Marrow Failure Syndromes</h1>
            <p>
              A complete, clinically actionable deep dive for haematologists, physicians, and trainees. Build rapid diagnostic intuition,
              master genetic subtypes, and translate the chapter into bedside decisions.
            </p>
            <div class="cta-row">
              <button class="cta-primary" id="startLearning">Start learning</button>
              <a class="cta-secondary" href="#module-3">Jump to Fanconi anaemia</a>
            </div>
          </div>
          <div class="hero-panel">
            <div class="panel-title">Fast facts from the chapter</div>
            <div class="stat-grid">
              <div class="stat"><span>Inherited syndromes in AA</span><strong>~20-30%</strong></div>
              <div class="stat"><span>FA: BMF by age 40</span><strong>~90%</strong></div>
              <div class="stat"><span>DC: BM abnormalities by age 30</span><strong>80-90%</strong></div>
              <div class="stat"><span>DBA incidence</span><strong>~5 per million births</strong></div>
            </div>
          </div>
        </div>
      </header>

      <section class="section" id="app">
        <div class="control-bar">
          <strong>Learning controls</strong>
          <button class="toggle" id="simplifyToggle" aria-pressed="false">Simplify view</button>
          <input class="search" id="searchInput" placeholder="Search by syndrome, gene, or feature" />
          <span class="cta-secondary">Tip: simplify view hides deep-dive panels.</span>
        </div>

        <div class="section-title">Learning map</div>
        <div class="section-sub">
          Navigate the entire chapter in structured modules. Each module contains core guidance, deep dive tables,
          and high-yield callouts.
        </div>

        <div class="map">
          <div class="map-card">
            <strong>Module 1</strong>
            <div>Foundations & phenotypes</div>
            <button data-target="#module-1">Open module</button>
          </div>
          <div class="map-card">
            <strong>Module 2</strong>
            <div>Diagnostic framework & tests</div>
            <button data-target="#module-2">Open module</button>
          </div>
          <div class="map-card">
            <strong>Module 3</strong>
            <div>Fanconi anaemia (FA)</div>
            <button data-target="#module-3">Open module</button>
          </div>
          <div class="map-card">
            <strong>Module 4</strong>
            <div>Dyskeratosis congenita (DC)</div>
            <button data-target="#module-4">Open module</button>
          </div>
          <div class="map-card">
            <strong>Module 5</strong>
            <div>Shwachman-Diamond syndrome</div>
            <button data-target="#module-5">Open module</button>
          </div>
          <div class="map-card">
            <strong>Module 6</strong>
            <div>Diamond-Blackfan anaemia</div>
            <button data-target="#module-6">Open module</button>
          </div>
          <div class="map-card">
            <strong>Module 7</strong>
            <div>Congenital dyserythropoietic anaemia</div>
            <button data-target="#module-7">Open module</button>
          </div>
          <div class="map-card">
            <strong>Module 8</strong>
            <div>Congenital & cyclic neutropenias</div>
            <button data-target="#module-8">Open module</button>
          </div>
          <div class="map-card">
            <strong>Module 9</strong>
            <div>TAR & CAMT thrombocytopenias</div>
            <button data-target="#module-9">Open module</button>
          </div>
          <div class="map-card">
            <strong>Module 10</strong>
            <div>New/overlapping BMF syndromes</div>
            <button data-target="#module-10">Open module</button>
          </div>
          <div class="map-card">
            <strong>Module 11</strong>
            <div>High-yield consolidation</div>
            <button data-target="#module-11">Open module</button>
          </div>
        </div>

        <section class="module" id="module-1">
          <div class="module-head">
            <h3>Module 1: Foundations & phenotypes</h3>
            <span class="module-tag">Orientation</span>
          </div>
          <div class="module-grid">
            <div class="card">
              <h4>Why inherited BMF matters</h4>
              <ul>
                <li>Inherited syndromes account for roughly 20-30% of patients presenting with aplastic anaemia.</li>
                <li>Phenotypes vary from single-lineage cytopenias to pan-lineage bone marrow failure.</li>
                <li>Clinical anomalies are common, but up to one-third of FA patients have no obvious physical signs.</li>
                <li>Accurate classification drives safer conditioning for HSCT and tailored surveillance for malignancy.</li>
              </ul>
            </div>
            <div class="card deep">
              <h4>Inherited BMF syndromes (Table 30.1)</h4>
              <div class="table-wrap">
                <table>
                  <thead>
                    <tr>
                      <th>Category</th>
                      <th>Typical syndromes</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td>Pancytopenia / global BMF</td>
                      <td>Fanconi anaemia, dyskeratosis congenita, Shwachman-Diamond syndrome, reticular dysgenesis, Pearson syndrome, familial aplastic anaemia, myelodysplasia, non-haematologic syndromes (Down, Dubowitz)</td>
                    </tr>
                    <tr>
                      <td>Single cytopenia: anaemia</td>
                      <td>Diamond-Blackfan anaemia, congenital dyserythropoietic anaemia</td>
                    </tr>
                    <tr>
                      <td>Single cytopenia: neutropenia</td>
                      <td>Severe congenital neutropenia (including Kostmann), cyclic neutropenia</td>
                    </tr>
                    <tr>
                      <td>Single cytopenia: thrombocytopenia</td>
                      <td>Congenital amegakaryocytic thrombocytopenia, thrombocytopenia with absent radii</td>
                    </tr>
                  </tbody>
                </table>
              </div>
            </div>
          </div>
          <div class="callout">
            <strong>Clinical anchor</strong>
            <div>Presence of somatic or extra-haematopoietic abnormalities alongside AA strongly suggests constitutional or inherited AA.</div>
          </div>
          <div class="card deep" style="margin-top: 18px;">
            <h4>Common somatic abnormalities in FA (Table 30.2)</h4>
            <div class="table-wrap">
              <table>
                <thead>
                  <tr>
                    <th>Abnormality</th>
                    <th>Approx. frequency (%)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr><td>Skeletal (radial ray, vertebral, scoliosis, ribs)</td><td>71</td></tr>
                  <tr><td>Skin pigmentation (cafe-au-lait, hyper/hypopigmentation)</td><td>64</td></tr>
                  <tr><td>Short stature</td><td>63</td></tr>
                  <tr><td>Eyes (microphthalmia)</td><td>38</td></tr>
                  <tr><td>Renal and urinary tract</td><td>34</td></tr>
                  <tr><td>Male genital anomalies</td><td>20</td></tr>
                  <tr><td>Mental retardation</td><td>16</td></tr>
                  <tr><td>GI anomalies (anorectal/duodenal atresia)</td><td>14</td></tr>
                  <tr><td>Cardiac anomalies</td><td>13</td></tr>
                  <tr><td>Hearing loss</td><td>9</td></tr>
                  <tr><td>CNS anomalies (hydrocephalus/septum pellucidum)</td><td>8</td></tr>
                  <tr><td>No abnormalities</td><td>30</td></tr>
                </tbody>
              </table>
            </div>
          </div>
        </section>

        <section class="module" id="module-2">
          <div class="module-head">
            <h3>Module 2: Diagnostic framework & tests</h3>
            <span class="module-tag">Workup</span>
          </div>
          <div class="module-grid">
            <div class="card">
              <h4>Actionable diagnostic algorithm</h4>
              <div class="flow">
                <div class="flow-step"><span>1</span>Identify AA/BMF or single-lineage cytopenia + family history or congenital features.</div>
                <div class="flow-step"><span>2</span>Baseline labs: CBC with indices, reticulocytes, fetal Hb, erythrocyte ADA, marrow cellularity.</div>
                <div class="flow-step"><span>3</span>Phenotype-driven screening: DEB/MMC breakage (FA), telomere length (DC), pancreatic function (SDS), marrow morphology (CDA), neutrophil studies (SCN).</div>
                <div class="flow-step"><span>4</span>Targeted NGS panel (syndrome-specific) + constitutional karyotype.</div>
                <div class="flow-step"><span>5</span>Confirm diagnosis, counsel family, and plan HSCT conditioning safely.</div>
              </div>
            </div>
            <div class="card deep">
              <h4>Core diagnostic tests (Table 30.13)</h4>
              <div class="table-wrap">
                <table>
                  <thead>
                    <tr>
                      <th>Test</th>
                      <th>Diagnostic value</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr><td>Fetal haemoglobin</td><td>High level suggests generalized BMF.</td></tr>
                    <tr><td>DEB/MMC-induced chromosomal breakage</td><td>Elevated in FA.</td></tr>
                    <tr><td>Telomere length</td><td>Short in AA, very short in DC.</td></tr>
                    <tr><td>Ham test / CD59 analysis</td><td>Abnormal in paroxysmal nocturnal haemoglobinuria.</td></tr>
                    <tr><td>Mitochondrial DNA analysis</td><td>Deletions seen in Pearson syndrome.</td></tr>
                    <tr><td>X-chromosome inactivation patterns</td><td>Skewed in carriers of X-linked DC.</td></tr>
                    <tr><td>Constitutional karyotype</td><td>Suggests inherited AA if abnormal.</td></tr>
                  </tbody>
                </table>
              </div>
              <details>
                <summary>Show gene panel checklist by syndrome</summary>
                <div style="margin-top: 12px; display: grid; gap: 10px;">
                  <div><strong>FA panel:</strong> FANCA to FANCW.</div>
                  <div><strong>DC/telomere disorders:</strong> DKC1, TERC, TERT, NOP10, NHP2, TINF2, TCAB1/WRAP53, USB1, CTC1, RTEL1, ACD/TPP1, PARN, NAF1, ZCCHC8, NPM1, MDM4, POT1, RPA1, DCLRE1B, TYMS-ENOSF1.</div>
                  <div><strong>SDS/SDS-like:</strong> SBDS, DNAJC21, EFL1, SRP54.</div>
                  <div><strong>DBA/DBA-like:</strong> RPS19, RPS7, RPS10, RPS15, RPS17, RPS24, RPS26, RPS27, RPS28, RPS29, RPL5, RPL9, RPL11, RPL15, RPL18, RPL26, RPL27, RPL31, RPL35A, GATA1, TSR2, EPO.</div>
                  <div><strong>CDA/CDA-like:</strong> CDAN1, CDIN1, SEC23B, KIF23, KLF1.</div>
                  <div><strong>Congenital/cyclic neutropenia:</strong> ELANE, HAX1, GFI1, G6PC3, VPS45, JAG1.</div>
                  <div><strong>CAMT/TAR syndromic thrombocytopenia:</strong> MPL, RBM8A, HOXA11, MECOM.</div>
                  <div><strong>New BMF syndromes:</strong> TPO/THPO, ERCC6L2, MYSM1, DUT, EXOC3L2, TP53, SPI1.</div>
                  <div><strong>Familial MDS/AML overlap:</strong> RUNX1, CEBPA, GATA2, SAMD9, SAMD9L, TERC, TERT, SRP72, ANKRD26, ETV6, DDX41, RTEL1, PAX5, TP53, ACD, MECOM, HLTF, XPC, DHX34.</div>
                </div>
              </details>
            </div>
          </div>
          <div class="card deep" style="margin-top: 18px;">
            <h4>Other investigations in suspected inherited BMF</h4>
            <div class="table-wrap">
              <table>
                <thead>
                  <tr>
                    <th>Investigation</th>
                    <th>Why it matters</th>
                  </tr>
                </thead>
                <tbody>
                  <tr><td>Skeletal survey</td><td>Identify skeletal anomalies (FA, TAR, SDS).</td></tr>
                  <tr><td>Abdominal ultrasound</td><td>Assess renal, hepatic or splenic anomalies.</td></tr>
                  <tr><td>Pulmonary function tests</td><td>Evaluate pulmonary complications (DC).</td></tr>
                  <tr><td>Echocardiogram</td><td>Screen cardiac defects (FA, DBA).</td></tr>
                  <tr><td>Exocrine pancreatic function</td><td>Abnormal in SDS and Pearson syndrome.</td></tr>
                  <tr><td>Neutrophil chemotaxis</td><td>Abnormal in SDS.</td></tr>
                  <tr><td>Fibroblast cultures</td><td>Abnormalities seen in DC.</td></tr>
                </tbody>
              </table>
            </div>
          </div>
        </section>

        <section class="module" id="module-3">
          <div class="module-head">
            <h3>Module 3: Fanconi anaemia (FA)</h3>
            <span class="module-tag">Global BMF</span>
          </div>
          <div class="module-grid">
            <div class="card">
              <h4>Clinical features</h4>
              <ul>
                <li>Autosomal recessive disorder (X-linked rare) with progressive BMF.</li>
                <li>Somatic anomalies: cafe-au-lait, radial ray defects, skeletal, GU, GI, cardiac, neuro anomalies.</li>
                <li>Up to one-third have no obvious physical abnormalities.</li>
                <li>Blood counts often normal at birth; pancytopenia develops insidiously, median age 7 years.</li>
                <li>Cumulative BMF by age 40 is ~90%.</li>
                <li>Median survival in IFAR cohort was 24 years (improving with modern care).</li>
              </ul>
            </div>
            <div class="card deep">
              <h4>Malignancy risk</h4>
              <ul>
                <li>AML common, often FAB M4/M5.</li>
                <li>Hematologic malignancy incidence ~33% by age 40.</li>
                <li>Solid tumors ~28% by age 40 (hepatic tumors, SCC of vulva, esophagus, head/neck).</li>
                <li>Median age: leukemia 13 years, solid tumors 25 years.</li>
              </ul>
            </div>
          </div>
          <div class="module-grid" style="margin-top: 18px;">
            <div class="card deep">
              <h4>FA/BRCA pathway (Figma-style diagram)</h4>
              <svg class="diagram" viewBox="0 0 820 360" role="img" aria-label="FA-BRCA pathway">
                <rect x="20" y="30" width="240" height="70" rx="16" fill="#f4d8dd" stroke="#8b0e1c" />
                <text x="40" y="70" font-size="16" font-weight="600" fill="#2b2f3a">FA Core Complex</text>
                <text x="40" y="92" font-size="12" fill="#2b2f3a">FANCA/B/C/E/F/G/L/M</text>

                <rect x="300" y="30" width="210" height="70" rx="16" fill="#cde8e4" stroke="#0f766e" />
                <text x="320" y="70" font-size="16" font-weight="600" fill="#0f766e">I-D2 Complex</text>
                <text x="320" y="92" font-size="12" fill="#0f766e">FANCI-FANCD2</text>

                <rect x="560" y="30" width="230" height="70" rx="16" fill="#fef1e4" stroke="#d7a35d" />
                <text x="580" y="70" font-size="16" font-weight="600" fill="#8b0e1c">DNA Repair</text>
                <text x="580" y="92" font-size="12" fill="#8b0e1c">BRCA1/2, RAD51, SLX4</text>

                <rect x="120" y="160" width="240" height="70" rx="16" fill="#f5f6fb" stroke="#5c6170" />
                <text x="140" y="200" font-size="15" font-weight="600" fill="#2b2f3a">ATR/ATM Signaling</text>
                <text x="140" y="222" font-size="12" fill="#5c6170">Replication stress response</text>

                <rect x="420" y="160" width="320" height="70" rx="16" fill="#f5f6fb" stroke="#5c6170" />
                <text x="440" y="200" font-size="15" font-weight="600" fill="#2b2f3a">Genome Stability Outcomes</text>
                <text x="440" y="222" font-size="12" fill="#5c6170">Chromosomal breakage, p53 activation, apoptosis</text>

                <line x1="260" y1="65" x2="300" y2="65" stroke="#8b0e1c" stroke-width="2" />
                <line x1="510" y1="65" x2="560" y2="65" stroke="#8b0e1c" stroke-width="2" />
                <line x1="240" y1="100" x2="240" y2="160" stroke="#8b0e1c" stroke-width="2" />
                <line x1="520" y1="100" x2="520" y2="160" stroke="#8b0e1c" stroke-width="2" />
                <line x1="360" y1="195" x2="420" y2="195" stroke="#5c6170" stroke-width="2" />
              </svg>
            </div>
            <div class="card">
              <h4>Diagnostics & genetics</h4>
              <ul>
                <li>Chromosomal breakage after DEB/MMC remains a useful screening test.</li>
                <li>22 complementation groups; FA-A, -C, -G are most common.</li>
                <li>FA-D1 (BRCA2) and FA-N (PALB2) carry high risk of childhood solid tumors.</li>
                <li>Somatic mosaicism can lead to improved counts (natural gene therapy).</li>
              </ul>
            </div>
          </div>
          <details style="margin-top: 18px;">
            <summary>FA complementation groups (Table 30.4)</summary>
            <div class="table-wrap" style="margin-top: 12px;">
              <table>
                <thead>
                  <tr>
                    <th>Group / Gene</th>
                    <th>Approx %</th>
                    <th>Chromosome</th>
                  </tr>
                </thead>
                <tbody>
                  <tr><td>FANCA</td><td>65</td><td>16q24.3</td></tr>
                  <tr><td>FANCB</td><td>&lt;1</td><td>Xp22.2</td></tr>
                  <tr><td>FANCC</td><td>12</td><td>9q22.3</td></tr>
                  <tr><td>FANCD1 (BRCA2)</td><td>&lt;1</td><td>13q13.1</td></tr>
                  <tr><td>FANCD2</td><td>&lt;1</td><td>3p25.3</td></tr>
                  <tr><td>FANCE</td><td>4</td><td>6p21.31</td></tr>
                  <tr><td>FANCF</td><td>4</td><td>1p14.3</td></tr>
                  <tr><td>FANCG</td><td>2</td><td>9p13.3</td></tr>
                  <tr><td>FANCI</td><td>&lt;1</td><td>15q26.1</td></tr>
                  <tr><td>FANCJ (BRIP1)</td><td>&lt;5</td><td>17q23.2</td></tr>
                  <tr><td>FANCL</td><td>&lt;1</td><td>2p16.1</td></tr>
                  <tr><td>FANCM</td><td>&lt;1</td><td>14q21.2</td></tr>
                  <tr><td>FANCN (PALB2)</td><td>&lt;1</td><td>16p12.2</td></tr>
                  <tr><td>FANCO (RAD51C)</td><td>&lt;1</td><td>17q22</td></tr>
                  <tr><td>FANCP (SLX4)</td><td>2</td><td>16p13.3</td></tr>
                  <tr><td>FANCQ (ERCC4)</td><td>&lt;1</td><td>16p13.12</td></tr>
                  <tr><td>FANCR (RAD51)</td><td>&lt;1</td><td>15q15.1</td></tr>
                  <tr><td>FANCS (BRCA1)</td><td>&lt;1</td><td>17q21.31</td></tr>
                  <tr><td>FANCT (UBE2T)</td><td>&lt;1</td><td>1q32.1</td></tr>
                  <tr><td>FANCU (XRCC2)</td><td>&lt;1</td><td>7q36.1</td></tr>
                  <tr><td>FANCV (REV7)</td><td>&lt;1</td><td>1p36.22</td></tr>
                  <tr><td>FANCW (RFWD3)</td><td>&lt;1</td><td>16p23.1</td></tr>
                </tbody>
              </table>
            </div>
          </details>
          <div class="callout high-yield">
            <strong>High yield</strong>
            <div>FA patients are hypersensitive to cyclophosphamide and radiation. HSCT conditioning must be reduced-intensity to avoid toxicity.</div>
          </div>
        </section>

        <section class="module" id="module-4">
          <div class="module-head">
            <h3>Module 4: Dyskeratosis congenita (DC)</h3>
            <span class="module-tag">Telomere disorder</span>
          </div>
          <div class="module-grid">
            <div class="card">
              <h4>Clinical core</h4>
              <ul>
                <li>Mucocutaneous triad: abnormal skin pigmentation, nail dystrophy, mucosal leukoplakia.</li>
                <li>Multi-system involvement: dental, GI, GU, neuro, pulmonary, skeletal.</li>
                <li>Skin/nail changes often by age 10; BMF typically before 20.</li>
                <li>80-90% develop BM abnormalities by age 30.</li>
              </ul>
            </div>
            <div class="card deep">
              <h4>Diagnostic anchors</h4>
              <ul>
                <li>Minimal criteria: at least two major features (skin pigmentation, nail dystrophy, leukoplakia, BMF) plus two other features.</li>
                <li>Main causes of death: BMF/immunodeficiency (~60-70%), pulmonary complications (~10-15%), malignancy (~10%).</li>
                <li>X-linked, AD, and AR inheritance patterns.</li>
              </ul>
            </div>
          </div>
          <div class="module-grid" style="margin-top: 18px;">
            <div class="card deep">
              <h4>Telomere biology (Figma-style diagram)</h4>
              <svg class="diagram" viewBox="0 0 820 360" role="img" aria-label="Telomere biology in DC">
                <rect x="30" y="30" width="230" height="80" rx="18" fill="#f4d8dd" stroke="#8b0e1c" />
                <text x="50" y="70" font-size="16" font-weight="600" fill="#2b2f3a">Telomerase Core</text>
                <text x="50" y="92" font-size="12" fill="#2b2f3a">TERT + TERC + DKC1</text>

                <rect x="300" y="30" width="230" height="80" rx="18" fill="#cde8e4" stroke="#0f766e" />
                <text x="320" y="70" font-size="16" font-weight="600" fill="#0f766e">Shelterin/Partners</text>
                <text x="320" y="92" font-size="12" fill="#0f766e">TINF2, POT1, ACD, RTEL1</text>

                <rect x="570" y="30" width="220" height="80" rx="18" fill="#fef1e4" stroke="#d7a35d" />
                <text x="590" y="70" font-size="16" font-weight="600" fill="#8b0e1c">Telomere Length</text>
                <text x="590" y="92" font-size="12" fill="#8b0e1c">Very short in DC</text>

                <rect x="170" y="170" width="480" height="90" rx="18" fill="#f5f6fb" stroke="#5c6170" />
                <text x="200" y="210" font-size="16" font-weight="600" fill="#2b2f3a">Phenotype</text>
                <text x="200" y="232" font-size="12" fill="#5c6170">BMF, pulmonary fibrosis, mucocutaneous triad, malignancy risk</text>

                <line x1="260" y1="70" x2="300" y2="70" stroke="#8b0e1c" stroke-width="2" />
                <line x1="530" y1="70" x2="570" y2="70" stroke="#8b0e1c" stroke-width="2" />
                <line x1="410" y1="110" x2="410" y2="170" stroke="#5c6170" stroke-width="2" />
              </svg>
            </div>
            <div class="card">
              <h4>Genetic subtypes (Table 30.6)</h4>
              <p>DC genes cluster into telomerase and shelterin pathways. XLR DKC1 is classic; AD and AR forms involve TERT/TERC and multiple telomere regulators.</p>
              <details>
                <summary>Show key DC genes by inheritance</summary>
                <div style="margin-top: 10px; display: grid; gap: 8px;">
                  <div><strong>X-linked:</strong> DKC1 (dyskerin).</div>
                  <div><strong>Autosomal dominant:</strong> TINF2, TERC, TERT, NAF1, ZCCHC8, NPM1, ACD/TPP1, RTEL1, RPA1, MDM4, POT1.</div>
                  <div><strong>Autosomal recessive:</strong> USB1, TYMS-ENOSF1, RTEL1, PARN, NOP10, TERT, NHP2, WRAP53/TCAB1, CTC1.</div>
                </div>
              </details>
            </div>
          </div>
          <div class="callout">
            <strong>Treatment essentials</strong>
            <div>Oxymetholone responds in ~two-thirds (0.25 mg/kg/day up to 2-5 mg/kg/day). Danazol is increasingly first-line. HSCT is curative but high risk due to pulmonary/vascular complications; fludarabine-based non-myeloablative protocols show lower toxicity.</div>
          </div>
        </section>

        <section class="module" id="module-5">
          <div class="module-head">
            <h3>Module 5: Shwachman-Diamond syndrome (SDS)</h3>
            <span class="module-tag">Ribosomopathy</span>
          </div>
          <div class="module-grid">
            <div class="card">
              <h4>Clinical triad</h4>
              <ul>
                <li>Exocrine pancreatic insufficiency (100%) with early malabsorption and failure to thrive.</li>
                <li>Bone marrow failure (100%), often neutropenia.</li>
                <li>Skeletal abnormalities: metaphyseal dysostosis (~75%).</li>
              </ul>
            </div>
            <div class="card deep">
              <h4>Key features</h4>
              <ul>
                <li>Short stature (~70%), protuberant abdomen, ichthyotic rash (~60%).</li>
                <li>Neutropenia (~60%), pancytopenia (~20%).</li>
                <li>MDS/AML risk ~25%, AML common (age 1-43 years).</li>
                <li>Differential: Pearson syndrome (ringed sideroblasts, mitochondrial DNA defects).</li>
                <li>Non-haematological malignancies have not been observed in SDS.</li>
              </ul>
            </div>
          </div>
          <div class="module-grid" style="margin-top: 18px;">
            <div class="card deep">
              <h4>Ribosome biogenesis diagram</h4>
              <svg class="diagram" viewBox="0 0 820 360" role="img" aria-label="Ribosome biogenesis">
                <rect x="40" y="40" width="260" height="90" rx="18" fill="#f5f6fb" stroke="#5c6170" />
                <text x="65" y="80" font-size="16" font-weight="600" fill="#2b2f3a">45S rRNA</text>
                <text x="65" y="102" font-size="12" fill="#5c6170">Processed into 18S, 5.8S, 28S</text>

                <rect x="360" y="40" width="180" height="90" rx="18" fill="#cde8e4" stroke="#0f766e" />
                <text x="385" y="80" font-size="16" font-weight="600" fill="#0f766e">40S</text>
                <text x="385" y="102" font-size="12" fill="#0f766e">RPS genes (DBA)</text>

                <rect x="580" y="40" width="180" height="90" rx="18" fill="#f4d8dd" stroke="#8b0e1c" />
                <text x="605" y="80" font-size="16" font-weight="600" fill="#8b0e1c">60S</text>
                <text x="605" y="102" font-size="12" fill="#8b0e1c">SBDS, EFL1, DNAJC21</text>

                <rect x="260" y="200" width="300" height="90" rx="18" fill="#fef1e4" stroke="#d7a35d" />
                <text x="290" y="240" font-size="16" font-weight="600" fill="#8b0e1c">80S Ribosome</text>
                <text x="290" y="262" font-size="12" fill="#8b0e1c">Final translation complex</text>

                <line x1="300" y1="85" x2="360" y2="85" stroke="#5c6170" stroke-width="2" />
                <line x1="540" y1="85" x2="580" y2="85" stroke="#5c6170" stroke-width="2" />
                <line x1="450" y1="130" x2="410" y2="200" stroke="#5c6170" stroke-width="2" />
                <line x1="670" y1="130" x2="480" y2="200" stroke="#5c6170" stroke-width="2" />
              </svg>
            </div>
            <div class="card">
              <h4>Genetics & management</h4>
              <ul>
                <li>SBDS variants in &gt;90% of cases; DNAJC21, EFL1 (AR) and SRP54 (AD) cause SDS-like disease.</li>
                <li>Pancreatic enzymes for malabsorption; G-CSF for neutropenia.</li>
                <li>Oxymetholone can improve anemia/thrombocytopenia.</li>
                <li>Leukemia often poor prognosis; HSCT with fludarabine conditioning preferred.</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="module" id="module-6">
          <div class="module-head">
            <h3>Module 6: Diamond-Blackfan anaemia (DBA)</h3>
            <span class="module-tag">Pure red cell aplasia</span>
          </div>
          <div class="module-grid">
            <div class="card">
              <h4>Diagnostic criteria</h4>
              <ul>
                <li>Macrocytic (or normocytic) anemia in early childhood.</li>
                <li>Reticulocytopenia.</li>
                <li>Normocellular marrow with erythroblasts &lt;5%.</li>
                <li>Normal or slightly low WBC; platelets normal or high.</li>
                <li>Supportive: elevated eADA, macrocytosis, raised fetal Hb.</li>
              </ul>
            </div>
            <div class="card deep">
              <h4>DBA Registry highlights</h4>
              <ul>
                <li>Incidence ~5 per million live births; median presentation 8 weeks.</li>
                <li>93% present in first year; 79% initially steroid responsive.</li>
                <li>Actuarial survival &gt;40 years: 100% sustained remission, 87% steroid-maintained, 57% transfusion-dependent.</li>
                <li>Somatic anomalies in 47% (craniofacial, limb/hand, GU, cardiac).</li>
              </ul>
            </div>
          </div>
          <details style="margin-top: 18px;">
            <summary>DBA genetic subtypes (Table 30.8)</summary>
            <div class="table-wrap" style="margin-top: 12px;">
              <table>
                <thead>
                  <tr>
                    <th>Subtype / Gene</th>
                    <th>Approx %</th>
                  </tr>
                </thead>
                <tbody>
                  <tr><td>RPS19 (AD)</td><td>25</td></tr>
                  <tr><td>Large deletions (various)</td><td>10-20</td></tr>
                  <tr><td>RPL5</td><td>7</td></tr>
                  <tr><td>RPS26</td><td>7</td></tr>
                  <tr><td>RPL11</td><td>5</td></tr>
                  <tr><td>RPL35A</td><td>3</td></tr>
                  <tr><td>RPS10</td><td>3</td></tr>
                  <tr><td>RPS24</td><td>2-4</td></tr>
                  <tr><td>RPS17</td><td>1</td></tr>
                  <tr><td>Other RPS/RPL genes</td><td>&lt;1 each</td></tr>
                  <tr><td>GATA1 (X-linked)</td><td>&lt;1</td></tr>
                  <tr><td>TSR2 (X-linked)</td><td>&lt;1</td></tr>
                  <tr><td>Uncharacterised</td><td>~25</td></tr>
                </tbody>
              </table>
            </div>
          </details>
          <div class="callout">
            <strong>Treatment pathway</strong>
            <div>Corticosteroids first-line; taper to lowest alternate-day dose. If refractory, transfusion support with early iron chelation (avoid deferiprone). Splenectomy for hypersplenism. HSCT for transfusion-dependent patients with HLA-matched donor.</div>
          </div>
        </section>

        <section class="module" id="module-7">
          <div class="module-head">
            <h3>Module 7: Congenital dyserythropoietic anaemia (CDA)</h3>
            <span class="module-tag">Dyserythropoiesis</span>
          </div>
          <div class="module-grid">
            <div class="card">
              <h4>CDA overview</h4>
              <ul>
                <li>Heterogeneous group with anemia and ineffective erythropoiesis.</li>
                <li>Classical types I, II, III; additional types IV-VII described.</li>
                <li>Characteristic marrow morphology and EM findings guide diagnosis.</li>
              </ul>
            </div>
            <div class="card deep">
              <h4>CDA type I (CDAN1/CDIN1)</h4>
              <ul>
                <li>Mild-moderate anemia (Hb ~66-116 g/L) with macrocytosis in ~70%.</li>
                <li>Marrow: megaloblastic precursors, internuclear chromatin bridges, 3-7% binuclearity.</li>
                <li>EM: spongy ‚ÄúSwiss cheese‚Äù heterochromatin.</li>
              </ul>
            </div>
          </div>
          <div class="module-grid" style="margin-top: 18px;">
            <div class="card deep">
              <h4>CDA type II (HEMPAS, SEC23B)</h4>
              <ul>
                <li>Most common subtype; anemia typically Hb 80-110 g/L.</li>
                <li>Jaundice, hepatomegaly, splenomegaly; ~10% need regular transfusions.</li>
                <li>BM: &gt;10% binucleate erythroblasts; EM shows peripheral double membranes.</li>
                <li>Acidified serum lysis (Ham test) usually positive.</li>
              </ul>
            </div>
            <div class="card">
              <h4>CDA type III (KIF23)</h4>
              <ul>
                <li>Rare, autosomal dominant; giant multinucleated erythroblasts.</li>
                <li>Increased prevalence of lymphoproliferative disorders reported.</li>
                <li>KIF23 encodes a mitotic kinesin important in cytokinesis.</li>
              </ul>
            </div>
          </div>
          <details style="margin-top: 18px;">
            <summary>CDA subtype comparison (Table 30.9)</summary>
            <div class="table-wrap" style="margin-top: 12px;">
              <table>
                <thead>
                  <tr>
                    <th>Feature</th>
                    <th>Type I</th>
                    <th>Type II</th>
                    <th>Type III</th>
                  </tr>
                </thead>
                <tbody>
                  <tr><td>Inheritance</td><td>AR</td><td>AR</td><td>AD</td></tr>
                  <tr><td>RBC indices</td><td>Macrocytic</td><td>Normocytic</td><td>Macrocytic</td></tr>
                  <tr><td>Light microscopy</td><td>Megaloblastic, chromatin bridges</td><td>Normoblastic, binuclearity</td><td>Megaloblastic, giant multinucleated</td></tr>
                  <tr><td>Electron microscopy</td><td>Swiss cheese heterochromatin</td><td>Peripheral double membranes</td><td>Non-specific</td></tr>
                  <tr><td>Ham test</td><td>Negative</td><td>Usually positive</td><td>Negative</td></tr>
                  <tr><td>Genes</td><td>CDAN1, CDIN1</td><td>SEC23B</td><td>KIF23</td></tr>
                </tbody>
              </table>
            </div>
          </details>
          <div class="callout">
            <strong>Treatment pearls</strong>
            <div>Folate for mild anemia. Transfusion and iron chelation if needed. Splenectomy can help CDA II. Interferon-alpha may improve CDA I. HSCT is rare but reported.</div>
          </div>
        </section>

        <section class="module" id="module-8">
          <div class="module-head">
            <h3>Module 8: Congenital & cyclic neutropenias</h3>
            <span class="module-tag">Neutropenia</span>
          </div>
          <div class="module-grid">
            <div class="card">
              <h4>Severe congenital neutropenia (SCN)</h4>
              <ul>
                <li>Neutrophils &lt;0.2 x 10^9/L at birth; Hb and platelets usually normal.</li>
                <li>Marrow maturation arrest at promyelocyte/myelocyte stage.</li>
                <li>Severe infections; MDS/AML risk ~25% by age 25.</li>
                <li>G-CSF dramatically improves outcome; HSCT if refractory or leukemia.</li>
              </ul>
            </div>
            <div class="card deep">
              <h4>Cyclic neutropenia</h4>
              <ul>
                <li>Neutrophil nadir every ~21 days.</li>
                <li>Fever and mouth ulcers around nadir.</li>
                <li>Usually autosomal dominant; ELANE variants common.</li>
                <li>ELANE mutations differ in location compared to SCN.</li>
              </ul>
            </div>
          </div>
          <details style="margin-top: 18px;">
            <summary>Genetic subtypes (Table 30.10)</summary>
            <div class="table-wrap" style="margin-top: 12px;">
              <table>
                <thead>
                  <tr>
                    <th>Inheritance</th>
                    <th>Approx %</th>
                    <th>Gene</th>
                  </tr>
                </thead>
                <tbody>
                  <tr><td>AD</td><td>50-60</td><td>ELANE</td></tr>
                  <tr><td>AD</td><td>2</td><td>GFI1</td></tr>
                  <tr><td>AR</td><td>10-15</td><td>HAX1</td></tr>
                  <tr><td>AR</td><td>5</td><td>G6PC3</td></tr>
                  <tr><td>Rare</td><td>Rare</td><td>VPS45</td></tr>
                  <tr><td>Rare</td><td>Rare</td><td>CSF3R</td></tr>
                  <tr><td>Rare</td><td>Rare</td><td>JAG1</td></tr>
                </tbody>
              </table>
            </div>
          </details>
          <div class="callout high-yield">
            <strong>High yield</strong>
            <div>No patient with SCN has developed aplastic anaemia, but risk of MDS/AML is substantial.</div>
          </div>
        </section>

        <section class="module" id="module-9">
          <div class="module-head">
            <h3>Module 9: TAR & CAMT thrombocytopenias</h3>
            <span class="module-tag">Thrombocytopenia</span>
          </div>
          <div class="module-grid">
            <div class="card">
              <h4>Thrombocytopenia with absent radii (TAR)</h4>
              <ul>
                <li>AR disorder: hypomegakaryocytic thrombocytopenia + bilateral radial aplasia.</li>
                <li>Bleeding at birth; platelet count often &lt;50 x 10^9/L.</li>
                <li>Leukocytes normal or high (leukaemoid reaction).</li>
                <li>Improves after infancy; prognosis excellent, no AA or leukemia reported.</li>
              </ul>
            </div>
            <div class="card deep">
              <h4>Congenital amegakaryocytic thrombocytopenia (CAMT)</h4>
              <ul>
                <li>Isolated thrombocytopenia with absent megakaryocytes.</li>
                <li>AR or X-linked; ~50% develop AA by age 5.</li>
                <li>MPL variants in a subgroup; HSCT is treatment of choice for severe cases.</li>
              </ul>
            </div>
          </div>
          <details style="margin-top: 18px;">
            <summary>Syndromic thrombocytopenia genes (Table 30.11)</summary>
            <div class="table-wrap" style="margin-top: 12px;">
              <table>
                <thead>
                  <tr>
                    <th>Subtype</th>
                    <th>Inheritance</th>
                    <th>Gene</th>
                  </tr>
                </thead>
                <tbody>
                  <tr><td>CAMT</td><td>AR</td><td>MPL</td></tr>
                  <tr><td>TAR</td><td>AR</td><td>RBM8A</td></tr>
                  <tr><td>Radio-ulnar synostosis</td><td>AD</td><td>HOXA11</td></tr>
                  <tr><td>Thrombocytopenia with MECOM</td><td>AD</td><td>MECOM</td></tr>
                </tbody>
              </table>
            </div>
          </details>
        </section>

        <section class="module" id="module-10">
          <div class="module-head">
            <h3>Module 10: New & overlapping BMF syndromes</h3>
            <span class="module-tag">Genomic era</span>
          </div>
          <div class="module-grid">
            <div class="card">
              <h4>Recently recognized BMF genes (Table 30.12)</h4>
              <ul>
                <li>AR: ERCC6L2, TPO/THPO, MYSM1, DUT, EXOC3L2, TP53.</li>
                <li>AD: SAMD9, SAMD9L, SPI1.</li>
                <li>Phenotypes overlap BMF, MDS, AML with extra-haematopoietic anomalies.</li>
              </ul>
            </div>
            <div class="card deep">
              <h4>Familial MDS/AML genes</h4>
              <p>Common AD genes include RUNX1, CEBPA, TERC, TERT, GATA2, SRP72, ANKRD26, ACD/TPP1, ETV6, DDX41, RTEL1, PAX5, SAMD9, SAMD9L, MECOM, TP53, ERBB3, DHX34.</p>
              <p>AR genes include MBD4, HLTF, XPC.</p>
            </div>
          </div>
          <div class="callout">
            <strong>Overlap reminder</strong>
            <div>GATA2 and SAMD9/SAMD9L variants are common in pediatric MDS with monosomy 7 and can present as isolated cytopenias.</div>
          </div>
        </section>

        <section class="module" id="module-11">
          <div class="module-head">
            <h3>Module 11: High-yield consolidation</h3>
            <span class="module-tag">Exam-ready</span>
          </div>
          <div class="module-grid">
            <div class="card">
              <h4>Rapid-fire contrasts</h4>
              <ul>
                <li>FA: DNA repair defect + chromosomal breakage; DEB/MMC positive.</li>
                <li>DC: telomere biology disorder; very short telomeres.</li>
                <li>SDS/DBA: ribosome biogenesis defects (ribosomopathies).</li>
                <li>SCN: promyelocyte arrest, G-CSF responsive, MDS/AML risk.</li>
                <li>TAR: thrombocytopenia + absent radii; improves after infancy.</li>
              </ul>
            </div>
            <div class="card deep">
              <h4>High-yield checklist</h4>
              <ul>
                <li>Look for congenital anomalies even in ‚Äúidiopathic‚Äù AA.</li>
                <li>Choose HSCT conditioning based on syndrome (FA/DC are highly sensitive).</li>
                <li>Use syndrome-targeted panels; avoid assuming single-gene disorders.</li>
                <li>Monitor malignancy risks long-term (FA, SDS, DBA).</li>
              </ul>
            </div>
          </div>
          <div class="quiz">
            <strong>Quick check</strong>
            <div>Which syndrome is characterized by the mucocutaneous triad of pigmentation, nail dystrophy, and leukoplakia?</div>
            <button class="reveal" data-reveal>Show answer</button>
            <div class="answer">Dyskeratosis congenita.</div>
          </div>
        </section>

        <div class="cta-band">
          <div>
            <h3>Teach, round, and revise with Bloodü©∏Doctor</h3>
            <p>Built from Chapter 30 for quick bedside recall and deeper learning.</p>
          </div>
          <button data-target="#top">Back to top</button>
        </div>

        <div class="disclaimer">
          Educational summary based on Hoffbrand Postgraduate Haematology (Chapter 30). Not medical advice. Follow institutional protocols.
        </div>
      </section>

      <footer class="footer">
        <div>Bloodü©∏Doctor ¬∑ Dr Abdul Mannan FRCPath FCPS</div>
        <div>blooddoctor.co@gmail.com</div>
      </footer>
    </div>

    <script>
      const simplifyToggle = document.getElementById("simplifyToggle");
      const searchInput = document.getElementById("searchInput");
      const startButton = document.getElementById("startLearning");

      startButton.addEventListener("click", () => {
        document.getElementById("app").scrollIntoView({ behavior: "smooth", block: "start" });
      });

      simplifyToggle.addEventListener("click", () => {
        const enabled = document.body.classList.toggle("simplify");
        simplifyToggle.setAttribute("aria-pressed", enabled);
        simplifyToggle.textContent = enabled ? "Show deep dive" : "Simplify view";
      });

      searchInput.addEventListener("input", () => {
        const query = searchInput.value.trim().toLowerCase();
        document.querySelectorAll(".module").forEach((module) => {
          const match = module.textContent.toLowerCase().includes(query);
          module.style.display = match ? "" : "none";
        });
      });

      document.querySelectorAll("[data-reveal]").forEach((button) => {
        button.addEventListener("click", () => {
          const answer = button.nextElementSibling;
          if (!answer) return;
          answer.classList.toggle("active");
          button.textContent = answer.classList.contains("active") ? "Hide answer" : "Show answer";
        });
      });

      document.querySelectorAll("[data-target]").forEach((button) => {
        button.addEventListener("click", () => {
          const target = document.querySelector(button.dataset.target);
          if (target) target.scrollIntoView({ behavior: "smooth", block: "start" });
        });
      });
    </script>
  </body>
</html>
